Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | DPP4 | P27487 | 7/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | TLR4 | O00206 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760630 | 1.00 | TSHR (0.75) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL1192792 | 1.00 | TSHR (0.75) | TSHRALDH1A1GAAEPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL2281880 | 0.99 | TSHR (0.73) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL3948461 | 0.92 | ALDH1A1 (0.85) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL381922 | 0.92 | ALDH1A1 (0.85) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL3948456 | 0.92 | ALDH1A1 (0.85) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL8324876 | 0.92 | TSHR (0.67) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL21198114 | 0.92 | TSHR (0.67) | TSHRALDH1A1GAAEPHX1DPP4 | |
| SCHEMBL14981586 | 0.92 | TSHR (0.67) | TSHRALDH1A1GAAEPHX1DPP4 | |
| Hydrochloric Acid SCHEMBL28135182 | 0.91 | ALDH1A1 (0.83) | TSHRALDH1A1GAAEPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250057827-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| WO-2024240840-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | BEACTICA THERAPEUTICS AB (SE) | 2024-11-28 | — | — | WO | disclosed |
| CN-112566697-B | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023161875-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161875-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2005095339-A1 | DICYANOPYRROLIDINES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-5925624-A | ANTIINFLAMMATORY AGENTS TREATING PATIENTS WITH INFLAMMATORY CONDITIONS SUSCEPTIBLE TO LEUKOCYTE-INDUCED TISSUE DAMAGE | GLAXO GROUP LIMITED (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0680488-B1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LTD (GB) | 1998-04-08 | — | — | EP | disclosed |
| EP-0680488-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017090-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | CDK1, MAPK1, NFATC1 | TSHR 1574/4885ALDH1A1 1013/4885GAA 1575/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | TSHR 156/4885ALDH1A1 2036/4885GAA 484/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TSHR 3690/4885ALDH1A1 2882/4885GAA 1937/4885 |
| US-20250057827-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS | CYTH2, CYTH3, CD47 | TSHR 2659/4885ALDH1A1 4431/4885GAA 2345/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | TSHR 2703/4885ALDH1A1 1912/4885GAA 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.